Abstract: Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug.

Abstract: Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug.

Abstract: Disclosed are a novel cyclotriphosphazene-platinum(II) complex conjugate anticancer agent, showing high selectivity to tumor tissues due to the enhanced permeability and retention effect in tumor tissues and a preparation method thereof.

Abstract: Disclosed are a novel cyclotriphosphazene-platinum(II) complex conjugate anticancer agent, showing high selectivity to tumor tissues due to the enhanced permeability and retention effect in tumor tissues and a preparation method thereof.

Abstract: Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug.

Abstract: Provided is a pharmaceutical composition for the treatment of liver cancer, including a layered metal hydroxide-retinoic acid (LMH-RA) hybrid as a novel drug delivery system which shows few side effects of retinoic acid, good drug stability, sustained drug release, and improved drug delivery efficiency.

Abstract: Provided are a hybrid of a poorly soluble basic drug and a layered silicate, including a water-soluble basic polymer, and a method of preparing the same. The water-soluble basic polymer may be an aminoalkylmethacrylate copolymer (e.g., Eudragit E 100: a copolymer composed of 1:2:1 ratio of butyl methacrylate, (2,2-dimethylaminoethyl)methacrylate, and methyl methacrylate, Degussa) or polyvinylacetal diethylaminoacetate (AEA). In an oral formulation including the hybrid, a short-term dissolution of the poorly soluble drug can be increased to 90%, thereby increasing drug bioavailability.

Abstract: The present invention provides a hybrid material comprised of an active component for raw materials for cosmetics and a layered metal hydroxide, showing good stability, low toxicity, low irritation, good sustained release and good dispersibility. The present invention provides a method for preparing the hybrid material, using the coprecipitation method, the ion-exchange method or the adsorption method, depending on properties of the active component for raw materials for cosmetics. The method may further comprise a step of coating the surface of the hybrid material after preparation of the hybrid material. The present invention provides cosmectics comprising the above hybrid material.

Abstract: The present invention provides the hybrids wherein itraconazole, cyclosporine or carvedilol are intercalated into the interlayers and/or absorbed onto the surfaces of layered silicates. The hybrids according to the present invention enable the maximization of bioavailability of drugs by dissolving the drugs from the layered silicates. Furthermore, the present invention provides the preparing methods of the hybrids.